Vol 4, No 7 (2024)

decorative image of the issue cover

Peer-Reviewed Article

National and International Policies on the Use of Biosimilars: An Environmental Scan

Jaemin Kim, Jessica Arias, Scott Gavura

Published July 4, 2024

PDF HTML

Reimbursement Recommendations

Atogepant (Qulipta)

CADTH

Published July 31, 2024

PDF HTML

Pembrolizumab (Keytruda)

CADTH

Published July 29, 2024

PDF HTML

Pembrolizumab (Keytruda)

CADTH

Published July 15, 2024

PDF HTML

Reimbursement Reviews

Drospirenone (Slynd)

CADTH

Published July 25, 2024

PDF HTML

Dostarlimab (Jemperli)

CADTH

Published July 24, 2024

PDF HTML

Cannabidiol (Epidiolex)

CADTH

Published July 23, 2024

PDF HTML

Inebilizumab (Uplizna)

CADTH

Published July 22, 2024

PDF HTML

Sotorasib (Lumakras)

CADTH

Published July 22, 2024

PDF HTML

Nirmatrelvir-Ritonavir (Paxlovid)

CADTH

Published July 9, 2024

PDF HTML

Health Technology Reviews

Drug Shortages: A Scoring System to Evaluate and Prioritize the Clinical Importance of Drugs in Canada

CADTH

Published July 31, 2024

PDF HTML

Strategies to Reduce Alternate Level of Care

CADTH

Published July 31, 2024

PDF HTML

Directly Observed Therapy in Correctional Settings

CADTH

Published July 29, 2024

PDF HTML

Re-Treatment With Immune Checkpoint Inhibitors

CADTH

Published July 23, 2024

PDF HTML

Auditory Verbal Therapy for Children With Hearing Loss

CADTH

Published July 18, 2024

PDF HTML

Review of Guidelines on Second-Line Therapy for Patients With Relapsing-Remitting Multiple Sclerosis: A 2024 Update

CADTH

Published July 18, 2024

PDF HTML

Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy

CADTH

Published July 12, 2024

PDF HTML

View All Issues